Pneumococcal Infections
📧 Sign up to get email alerts when something new happens for Pneumococcal Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-16EMA Authorised: Vaxneuvance (pneumococcal polysaccharide conjugate vaccine (adsorbed)) — Merck Sharp & Dohme B.V.
EMA authorises Vaxneuvance (pneumococcal polysaccharide conjugate vaccine, adsorbed) for pneumococcal infections.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine [Phase 1, Phase 2]
Phase 1/2 trial evaluating a 26-valent pneumococcal conjugate vaccine has been completed.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults [Phase 4]
Phase 4 clinical trial evaluating the immunogenicity and safety of the PCV-20 pneumococcal vaccine administered during acute febrile illness…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) [Phase 3]
This clinical trial update reports on a Phase 3 study to evaluate the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccin…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab [Phase 3]
A Phase 3 clinical trial evaluating a prime-boost anti-pneumococcal vaccination strategy in patients with diffuse large B-cell lymphoma trea…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 1]
Phase 1 trial evaluating the safety and immunogenicity of a 13-valent pneumococcal polysaccharide conjugate vaccine; the study status is com…
-
EMA approval · 2026-01-06EMA Authorised: Vaxneuvance (pneumococcal polysaccharide conjugate vaccine (adsorbed)) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Merck's Vaxneuvance, a pneumococcal polysaccharide conjugate vaccine (adsorbed), for pneumococcal i…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age [Phase 1]
This update describes a Phase 1 clinical trial evaluating the safety and immune response of an investigational pneumococcal vaccine in adult…
-
EMA approval · 2025-11-18EMA Authorised: Prevenar 20 (previously Apexxnar) (Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 3;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6A;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 8;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 10A;Pneumococcal polysaccharide serotype 11A;pneumococcal polysaccharide serotype 12F;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 15b;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19A;Pneumococcal polysaccharide serotype 19F;Pneumococcal polysaccharide serotype 22F;Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 33F) — Pfizer Europe MA EEIG
The EMA authorised Prevenar 20 (formerly Apexxnar), a 20-valent pneumococcal conjugate vaccine by Pfizer, for vaccination against pneumococc…
-
EMA approval · 2025-10-06EMA Authorised: Capvaxive (pneumococcal polysaccharide serotype 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B de-O-acetylated, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B conjugated to CRM197 carrier protein) — Merck Sharp & Dohme B.V.
EMA has authorised Capvaxive, a pneumococcal conjugate vaccine covering multiple serotypes and developed by Merck Sharp & Dohme B.V., for pr…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents [Phase 3]
Phase 3 trial investigating safety and immunogenicity of catch-up vaccination with PCV21 in healthy infants to adolescents.
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response [NA]
A completed clinical trial investigated which B cell subsets mediate the antibody response to pneumococcal pathogens, shedding light on immu…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People [Phase 4]
A Phase 4 clinical trial update evaluating the real-world effectiveness of a pneumococcal vaccination campaign in a camp for internally disp…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
This trial analyzes upper respiratory tract immune responses in older adults who are infected or colonized with Streptococcus pneumoniae, to…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine [Phase 3]
A Phase 3 study is evaluating the immunogenicity and safety of Minhai's PCV13-DT/TT vaccine versus Pfizer's PCV13 vaccine, and the trial is …
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Extension Safety and Immunogenicity Study of GPNV-001 [Phase 1, Phase 2]
Completion of an extension safety and immunogenicity study for the GPNV-001 vaccine candidate in pneumococcal infections (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders [Phase 1]
This Phase 1 trial reports immunogenicity and reactogenicity data for pneumococcal polysaccharide and conjugate vaccines in elderly particip…
-
CLINICAL_TRIALS research · 2024-09-24Clinical Trial Update: The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage [NA]
This clinical trial evaluates whether administering AUDIT (Alcohol Use Disorders Identification Test) and providing feedback can improve pne…
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. [Phase 1]
Phase 1 study evaluating safety, tolerability, and immunogenicity of Gamma-PN3, an inactivated whole-cell pneumococcal vaccine. The trial ha…
-
CLINICAL_TRIALS trial_result · 2024-08-19Clinical Trial Update: Immunization To Prevent Acute COPD Exacerbations
Pfizer conducted an immunization trial aimed at preventing acute exacerbations of chronic obstructive pulmonary disease, which has been term…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children [Phase 3]
Phase 3 trial of the 13-valent pneumococcal conjugate vaccine in healthy Chinese infants and young children has completed and results were p…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults [Phase 1, Phase 2]
Phase 1/2 trial update on the safety, tolerability, and immunogenicity of the 24-valent pneumococcal conjugate vaccine VAX-24 in adults; stu…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) [Phase 3]
Phase III clinical trial of a candidate PCV13 vaccine in healthy individuals aged 6 weeks and above has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels [Phase 4]
Phase 4 trial comparing sequential versus simultaneous pneumococcal vaccination in elderly, focusing on immunological memory and antibody re…
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) [Phase 1]
Phase 1 trial evaluating safety, tolerability, and immunogenicity of the V114 pneumococcal vaccine in healthy Japanese infants; the study is…